CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 9.38: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.30BCNY492.23M · vs all stocks (USD)
Revenue (TTM)
298.07MCNY44.48M · vs all stocks (USD)
Profit Margin
-48.46%Beta
0.0980xvs all stocks
52-Week Change
-39.54%vs all stocks
Market Capitalization
3.30BCNY492.23M · vs all stocks (USD)
Enterprise Value
3.33BCNY497.53M · vs all stocks (USD)
Price to Sales (TTM)
11.49xPrice to Book (MRQ)
1.93xEnterprise to Revenue
11.19xEnterprise to EBITDA
-21.75xGross Margin
12.41%Profit Margin
-48.46%Operating Margin
-114.42%Return on Assets (TTM)
-5.86%Return on Equity (TTM)
-9.32%Revenue (TTM)
298.07MCNY44.48M · vs all stocks (USD)
Revenue per Share (TTM)
0.4520CNYUpdated Sep 21, 2026Quarterly Revenue Growth
41.60%Gross Profit (TTM)
82.25MCNY12.27M · vs all stocks (USD)
EBITDA (TTM)
-153.32MCNY-22.88M · vs all stocks (USD)
Net Income (TTM)
-144.45MCNY-21.55M · vs all stocks (USD)
Operating Cash Flow (TTM)
-180.87MCNY-26.99M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-306.53MCNY-45.74M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
104.16MCNYFY2025 · Dec 31, 2025Revenue
274.81MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
129.60MCNYFY2025 · Dec 31, 2025Gross Profit
145.21MCNYFY2025 · Dec 31, 2025Operating Income
-142.22MCNY-21.22M · vs all stocks (USD)
Pre-tax Income
-175.53MCNYFY2025 · Dec 31, 2025Income Tax Expense
-14.70MCNYFY2025 · Dec 31, 2025Net Income
-160.83MCNYFY2025 · Dec 31, 2025EBIT
-174.41MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-79.33MCNYFY2025 · Dec 31, 2025Research & Development
18.87MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
253.89MCNYFY2025 · Dec 31, 2025Other Operating Expenses
6.14MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.28MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.12MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1763CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1763CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
659.58MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
659.58MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-160.83MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
44.55MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-384.72MCNYFY2025 · Dec 31, 2025Free Cash Flow
-560.35MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
203.97MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-160.83MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.39MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-230.18MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
4.91MCNYFY2025 · Dec 31, 2025Capital Expenditures
-175.63MCNYFY2025 · Dec 31, 2025Sale of Investments
134.55MCNYFY2025 · Dec 31, 2025Other Investing Activity
8.47MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-32.61MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
8.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-19.77MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.14MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.12MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-14.03MCNYFY2025 · Dec 31, 2025Shares Outstanding
659.74MSharesUpdated Sep 21, 2026Float Shares
494.62MSharesUpdated Sep 21, 2026% Held by Insiders
36.02%vs all stocks
% Held by Institutions
4.85%vs all stocks
Total Cash (MRQ)
242.84MCNY36.24M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3680CNYUpdated Sep 21, 2026Total Debt (MRQ)
58.15MCNY8.68M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0311xCurrent Ratio (MRQ)
4.64xBook Value per Share (MRQ)
2.69CNYUpdated Sep 21, 2026Total Assets
2.17BCNY323.56M · vs all stocks (USD)
Total Current Assets
629.34MCNYFY2025 · Dec 31, 2025Total Liabilities
222.00MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.54BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
31.22MCNYFY2025 · Dec 31, 2025Total Current Liabilities
190.78MCNYFY2025 · Dec 31, 2025Cash
213.39MCNYFY2025 · Dec 31, 2025Cash Equivalents
6.86MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
220.25MCNYFY2025 · Dec 31, 2025Other Short-term Investments
20.10KCNYFY2025 · Dec 31, 2025Accounts Receivable
266.47MCNYFY2025 · Dec 31, 2025Inventory
93.25MCNYFY2025 · Dec 31, 2025Accounts Payable
88.39MCNYFY2025 · Dec 31, 2025Short-term Debt
50.25MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.72MCNYFY2025 · Dec 31, 2025Long-term Debt
11.19MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
4.94MCNYFY2025 · Dec 31, 2025Common Stock (Book)
229.15MCNYFY2025 · Dec 31, 2025Retained Earnings
559.27MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.95BCNY290.44M · vs all stocks (USD)
52-Week Low
3.04CNYUpdated Sep 21, 202652-Week High
9.17CNYUpdated Sep 21, 202652-Week Change
-39.54%vs all stocks
Beta
0.0980xvs all stocks
50-Day MA
4.47CNYUpdated Sep 21, 2026200-Day MA
5.99CNYUpdated Sep 21, 2026Avg 10-Day Volume
5.84MSharesUpdated Sep 21, 2026Avg 30-Day Volume
13.14MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-0.2200CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 9.38: safe zoneNotable
Altman Z-Score: 9.38
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Nanhua Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Onconic Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Wuhan Hiteck Biological Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Daewoong Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Capricor Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo David Medical Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chison Medical Technologies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule